Clinical Trial Update: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial comparing JSKN003 to physician's choice for HER2-low, unresectable and/or metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• JSKN003

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING